<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707730</url>
  </required_header>
  <id_info>
    <org_study_id>AGY-010</org_study_id>
    <nct_id>NCT03707730</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease</brief_title>
  <acronym>AGY-010</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Persons With Celiac Disease Age &gt; 10 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igy Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vetanda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Igy Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of AGY vs placebo when administered to individuals age 10
      to 65 years with medically proven CD and on a gluten free diet
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a randomized double-blind, placebo-controlled crossover trial in 149
      individuals with celiac disease proven by biopsy (or other medically documented confirmation
      of CD, e.g. TTG counts &gt; 10 times the upper limit of normal on two occasions) at least 12
      months before study entry, and who are following a gluten-free diet but continue to have
      recurrent symptoms.

      AGY is designed to neutralize the hidden gliadin in food, thus preventing gliadin absorption
      and gliadin induced pathogenesis. The study will test whether AGY is safe and effective in
      the study population, versus placebo.

      Primary Objective: The primary objective will be to evaluate the effect of AGY on celiac
      symptoms using the daily Celiac Symptom Index (CSI).

      Secondary objectives: Secondary objectives will be to evaluate product safety and the effect
      of AGY on quality of life, autoantibodies, and gut permeability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized double-blind, placebo-controlled crossover trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms</measure>
    <time_frame>14 weeks</time_frame>
    <description>celiac related symptoms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>AGY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule containing egg yolk with AGY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsule containing plain egg yolk</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AGY</intervention_name>
    <description>oral AGY taken prior to meals</description>
    <arm_group_label>AGY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral placebo taken prior to meals</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of CD

          -  experience periodic celiac related symptoms

          -  following a gluten free diet for at least 12 months

        Exclusion Criteria:

          -  severe complications of CD or chronic active GI disease

          -  type 1 diabetic

          -  pregnant or breast feeding

          -  daily ASA/NSAID use

          -  any condition that in the opinion of the investigator, would preclude safe
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justine Turner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dory Sample, MSN, MPH</last_name>
    <phone>780-248-5599</phone>
    <email>dory.sample@ahs.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dory Sample, MSN, MPH</last_name>
      <phone>780-248-5599</phone>
      <email>dory.sample@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Justine Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leo Dieleman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

